After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?

Eli Lilly reported strong Q3 earnings driven by its weight loss drug portfolio, with Mounjaro and Zepbound sales surging 65% and 49% respectively. The company now holds 63% of the U.S. weight loss drug market, up from competitor Novo Nordisk. While the stock trades at a record high of $1,300+ at 42x forward earnings, analysts suggest significant growth potential remains as only 3-10% of potential patients currently access weight loss care, with additional pipeline candidates in development.